A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis
G Raghu, KK Brown, WZ Bradford… - … England Journal of …, 2004 - Mass Medical Soc
Background Idiopathic pulmonary fibrosis is a progressive, fatal disease with no known
efficacious therapy. Methods In a double-blind, multinational trial, we randomly assigned …
efficacious therapy. Methods In a double-blind, multinational trial, we randomly assigned …
Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial
Background Idiopathic pulmonary fibrosis is a fatal disease for which no effective treatment
exists. We assessed whether treatment with interferon gamma-1b improved survival …
exists. We assessed whether treatment with interferon gamma-1b improved survival …
A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis
R Ziesche, E Hofbauer, K Wittmann… - … England Journal of …, 1999 - Mass Medical Soc
Background Patients with idiopathic pulmonary fibrosis have progressive scarring of the
lung and usually die within four to five years after symptoms develop. Treatment with oral …
lung and usually die within four to five years after symptoms develop. Treatment with oral …
Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis
KM Antoniou, AG Nicholson, M Dimadi… - European …, 2006 - Eur Respiratory Soc
Idiopathic pulmonary fibrosis (IPF)/usual interstitial pneumonia is a deadly disease with no
effective treatment. The purpose of this randomised prospective multicentric study was to …
effective treatment. The purpose of this randomised prospective multicentric study was to …
The clinical course of patients with idiopathic pulmonary fibrosis
FJ Martinez, S Safrin, D Weycker, KM Starko… - Annals of internal …, 2005 - acpjournals.org
Background: Prospective data defining the clinical course in idiopathic pulmonary fibrosis
(IPF) are sparse. Objective: To analyze the clinical course of patients with mild to moderate …
(IPF) are sparse. Objective: To analyze the clinical course of patients with mild to moderate …
Analyses of efficacy end points in a controlled trial of interferon-γ1b for idiopathic pulmonary fibrosis
TE King Jr, S Safrin, KM Starko, KK Brown, PW Noble… - Chest, 2005 - Elsevier
Background Idiopathic pulmonary fibrosis (IPF) is a devastating disease, yet validated,
reliable criteria for evaluating patient response to therapies in clinical trials are lacking …
reliable criteria for evaluating patient response to therapies in clinical trials are lacking …
Effects of interferon-γ 1b on biomarker expression in patients with idiopathic pulmonary fibrosis
RM Strieter, KM Starko, RI Enelow, I Noth… - American journal of …, 2004 - atsjournals.org
In a recent study of IFN-γ 1b in 330 patients with idiopathic pulmonary fibrosis (IPF),
progression-free survival was unchanged; however, a trend toward lower mortality was seen …
progression-free survival was unchanged; however, a trend toward lower mortality was seen …
[HTML][HTML] Pharmacological therapy for idiopathic pulmonary fibrosis: past, present, and future
RJ Mason, MI Schwarz, GW Hunninghake… - American Journal of …, 1999 - atsjournals.org
Idiopathic pulmonary fibrosis (IPF) is a devastating illness for which current therapy is
minimally effective. If medical therapy for IPF is going to improve over the next decade …
minimally effective. If medical therapy for IPF is going to improve over the next decade …
Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials
G Raghu, HR Collard, KJ Anstrom… - American journal of …, 2012 - atsjournals.org
Definitive evidence of clinical efficacy in a Phase 3 trial is best shown by a beneficial impact
on a clinically meaningful endpoint—that is, an endpoint that directly measures how a …
on a clinically meaningful endpoint—that is, an endpoint that directly measures how a …
All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials
TE King Jr, C Albera, WZ Bradford… - American journal of …, 2014 - atsjournals.org
Rationale: FVC has emerged as a standard primary endpoint in clinical trials evaluating
novel therapies for patients with idiopathic pulmonary fibrosis (IPF). However, it has recently …
novel therapies for patients with idiopathic pulmonary fibrosis (IPF). However, it has recently …